← All trials
NCT05210530
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 24, 2022
- Primary completion
- Apr 30, 2023
- Completion date
- Apr 30, 2023
- First posted
- Jan 27, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CRISPR TherapeuticsLead sponsor
- ViaCyteCollaborator
- ViaCyteStudy director
- CRISPR TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.